OSE Therapeutics SA (OSE.PA), a clinical-stage biotechnology company, announced on Monday that the FDA has granted orphan drug designation to pegrizeprument in prophylaxis of heart allograft rejection after a heart transplant.
Pegrizeprument (VEL-101), a novel, investigational, immunomodulating, pegylated, monoclonal monovalent antibody fragment, was licensed to Veloxis Pharma in 2021. It acts by blocking CD28-mediated T-cell activation, allowing indirectly for the CTLA-4 mediated immunosuppressive function. Originally developed by OSE, it has been licensed by Veloxis for manufacture and commercialization.
Pegrizeprument received an orphan drug designation in January 2026 for preventing organ rejection in liver transplant cases and is currently being explored for treating rejection in solid organ transplants. OSE.PA is currently trading at $3.75, up 24.14%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.